Mesoblast (MESO) has released an update.
Mesoblast Limited announced its plans to file for FDA approval for Ryoncil, a treatment for acute graft versus host disease, with potential market entry in the second half of 2024. The company also highlighted ongoing Phase 3 programs for heart failure and back pain, and its strong U.S. intellectual property position, with patents potentially extending through 2043. Mesoblast is a global leader in allogeneic cellular medicines, with a broad portfolio targeting severe inflammatory conditions and a robust global intellectual property portfolio.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
